• Publications
  • Influence
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
TLDR
Treatment with peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate has few adverse effects and compares favorably to the limited number of alternative treatment modalities.
A step-up approach or open necrosectomy for necrotizing pancreatitis.
TLDR
A minimally invasive step-up approach, as compared with open necrosectomy, reduced the rate of the composite end point of major complications or death among patients with necrotizing pancreatitis and infected necrotic tissue.
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.
TLDR
Treatment with 177Lu-octreotate results in tumor remission in a high percentage of patients with GEP tumors, and results are better in patients with a limited tumor load.
Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial.
TLDR
In patients with infected necrotizing pancreatitis, endoscopic necrosectomy reduced the proinflammatory response as well as the composite clinical end point compared with surgical necro Sectomy.
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
TLDR
There is a benefit in overall survival of several years from the time of diagnosis in patients treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate, and if more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs.
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
TLDR
PRRT with 177Lu-DOTATATE is safe with few side-effects and shows good response rates with PFS of 29 months and OS of 63 months and is a favorable therapeutic option in patients with metastatic bronchial and gastroenteropancreatic NETs that express somatostatin receptors.
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
TLDR
Although the outcomes of the secondary end points and predefined subgroup analyses suggest an advantage of the neoadjuvant approach, additional evidence is required.
Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
TLDR
The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectables or borderline resectable pancreatic cancer.
Pylorus Preserving Pancreaticoduodenectomy Versus Standard Whipple Procedure: A Prospective, Randomized, Multicenter Analysis of 170 Patients With Pancreatic and Periampullary Tumors
TLDR
The SW and PPPD operations were associated with comparable operation time, blood loss, hospital stay, mortality, morbidity, and incidence of DGE; both surgical procedures are equally effective for the treatment of pancreatic and periampullary carcinoma.
...
1
2
3
4
5
...